JP2017515888A5 - - Google Patents

Download PDF

Info

Publication number
JP2017515888A5
JP2017515888A5 JP2017502766A JP2017502766A JP2017515888A5 JP 2017515888 A5 JP2017515888 A5 JP 2017515888A5 JP 2017502766 A JP2017502766 A JP 2017502766A JP 2017502766 A JP2017502766 A JP 2017502766A JP 2017515888 A5 JP2017515888 A5 JP 2017515888A5
Authority
JP
Japan
Prior art keywords
composition
shock
polyethylene glycol
electrolytes
aqueous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017502766A
Other languages
English (en)
Japanese (ja)
Other versions
JP6648106B2 (ja
JP2017515888A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/022198 external-priority patent/WO2015148474A1/en
Publication of JP2017515888A publication Critical patent/JP2017515888A/ja
Publication of JP2017515888A5 publication Critical patent/JP2017515888A5/ja
Application granted granted Critical
Publication of JP6648106B2 publication Critical patent/JP6648106B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017502766A 2014-03-25 2015-03-24 自己消化の治療用組成物 Expired - Fee Related JP6648106B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461970247P 2014-03-25 2014-03-25
US61/970,247 2014-03-25
US201462019007P 2014-06-30 2014-06-30
US62/019,007 2014-06-30
PCT/US2015/022198 WO2015148474A1 (en) 2014-03-25 2015-03-24 Compositions for the treatment of autodigestion

Publications (3)

Publication Number Publication Date
JP2017515888A JP2017515888A (ja) 2017-06-15
JP2017515888A5 true JP2017515888A5 (enExample) 2018-05-10
JP6648106B2 JP6648106B2 (ja) 2020-02-14

Family

ID=54188811

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017502766A Expired - Fee Related JP6648106B2 (ja) 2014-03-25 2015-03-24 自己消化の治療用組成物

Country Status (14)

Country Link
US (4) US9314442B2 (enExample)
EP (1) EP3122349B1 (enExample)
JP (1) JP6648106B2 (enExample)
KR (2) KR102397379B1 (enExample)
CN (3) CN112807325A (enExample)
AU (1) AU2015236283B2 (enExample)
CA (1) CA2942358C (enExample)
DK (1) DK3122349T3 (enExample)
ES (1) ES2906262T3 (enExample)
MX (1) MX376176B (enExample)
PL (1) PL3122349T3 (enExample)
PT (1) PT3122349T (enExample)
TW (2) TWI669114B (enExample)
WO (1) WO2015148474A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101820977B1 (ko) 2010-09-23 2018-01-22 인플라마겐 세린 프로테아제 억제제의 위로의 투여
KR102397379B1 (ko) 2014-03-25 2022-05-13 리딩 바이오사이언시즈, 인크. 자가소화의 치료용의 조성물
CN113908281B (zh) * 2016-01-11 2023-09-15 恒翼生物医药(上海)股份有限公司 用于治疗和预防粘连及肠梗阻的组合物和方法
US20200323803A1 (en) * 2017-10-24 2020-10-15 Leading BioSciences, Inc. Compositions and methods for glucose control
BE1025996A9 (fr) 2018-01-19 2020-05-11 Hyloris Dev Sa Solution orale d’acide tranexamique
CN110730413A (zh) * 2018-06-29 2020-01-24 阿里巴巴集团控股有限公司 一种终端定位方法和装置
US10980757B2 (en) 2018-09-06 2021-04-20 RTU Pharma SA Ready-to-use tranexamic acid intravenous solution

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56158707A (en) 1980-04-08 1981-12-07 Lion Corp Composition for oral use
JP3496158B2 (ja) 1993-01-26 2004-02-09 東洋カプセル株式会社 トラネキサム酸配合ゼラチンカプセル製剤
US5578568A (en) 1994-04-22 1996-11-26 Xoma Corporation Method of treating conditions associated with intestinal ischemia/reperfusion
DE19617369A1 (de) 1996-04-30 1997-11-06 Immuno Ag Lagerstabile Fibrinogen-Präparate
JP3940209B2 (ja) 1996-11-14 2007-07-04 株式会社資生堂 可溶化化粧料
US6121232A (en) 1997-01-31 2000-09-19 Omrix Biopharmaceuticals Sa Stabilized mixture comprising fibrinogen
AU9027298A (en) 1997-08-20 1999-03-08 Lxr Biotechnology Inc. Compositions containing polyethylene glycol and uses thereof
TWI243687B (en) 1998-04-21 2005-11-21 Teijin Ltd Pharmaceutical composition for application to mucosa
DE10025001A1 (de) 2000-05-22 2001-11-29 Aventis Behring Gmbh Gewebekleber mit verbesserten anti-adhäsiven Eigenschaften
US7276235B2 (en) 1998-11-18 2007-10-02 Zlb Behring Gmbh Tissue glue with improved antiadhesive properties
WO2001037854A1 (en) 1999-11-24 2001-05-31 The Regents Of The University Of California Method for treatment and prevention of physiological shock
US6708822B1 (en) * 1999-11-30 2004-03-23 Cutispharma, Inc. Compositions and kits for compounding pharmaceuticals
US20030144212A1 (en) 2000-07-06 2003-07-31 Hoffman Keith B Use of serine protease inhibitors to inhibit pathophysiology and neuropathology in a host
JP4044748B2 (ja) 2001-10-17 2008-02-06 サンスター株式会社 口腔用液体組成物
US20040018984A1 (en) 2002-07-17 2004-01-29 Mizuo Miyazaki Methods for preventing adhesion formation using protease inhibitors
GB0224909D0 (en) 2002-10-25 2002-12-04 Norgine Europe Bv Colon cleansing compositions
WO2004047778A1 (en) 2002-11-26 2004-06-10 Uc Tech Materials and methods for preventing and treating microbe-mediated epithelial disorders
US20050025825A1 (en) 2003-07-31 2005-02-03 Xanodyne Pharmacal, Inc. Tranexamic acid formulations with reduced adverse effects
JP2005068076A (ja) 2003-08-25 2005-03-17 Tendou Seiyaku Kk トラネキサム酸類を含む外用液剤および清拭剤
US20090215898A1 (en) 2004-03-04 2009-08-27 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
MXPA06012070A (es) * 2004-04-20 2007-04-24 Univ Chicago Sistema de surtido terapeutico que comprende un compuesto de tipo peg de peso molecular alto.
WO2007053194A2 (en) 2005-06-03 2007-05-10 The University Of Chicago Modulation of cell barrier dysfunction
MX2007015262A (es) 2005-06-03 2008-02-22 Univ Chicago Modulacion de interacciones de celulas huesped de patogenos microbianos.
US20080194611A1 (en) 2005-06-03 2008-08-14 Alverdy John C Modulation of Cell Barrier Dysfunction
WO2007101264A2 (en) 2006-02-28 2007-09-07 The University Of Chicago Method for treating endothelial and epithelial cell disorders by administering high molecular weight peg-like compounds
JP5465824B2 (ja) 2006-03-24 2014-04-09 第一三共ヘルスケア株式会社 医薬用製剤およびその製造方法
US20100179091A1 (en) 2007-02-20 2010-07-15 The Regents Of The University Of California Treatment of Conditions Related to Shock
JP5093841B2 (ja) 2007-07-12 2012-12-12 株式会社 資生堂 不織布含浸化粧料
WO2009045543A1 (en) 2007-10-04 2009-04-09 The Regents Of The University Of California Treatment of conditions related to shock
US20100226995A1 (en) 2007-11-12 2010-09-09 Debrouse Daniel R Microencapsulated bioactive agents for oral delivery and methods of use thereof
WO2010087874A1 (en) 2009-01-28 2010-08-05 Anazyme, Llc Compositions and methods for diagnosis of shock
WO2009132149A2 (en) 2008-04-22 2009-10-29 The Regents Of The University Of California Treatment of conditions related to cecal ligation shock
EP2294012B1 (en) 2008-05-07 2014-07-09 Salix Pharmaceuticals, Ltd. Administration of a bowel cleanser and an antibiotic for the treatment of bowel disease
US7635707B1 (en) * 2008-11-10 2009-12-22 Intermune, Inc. Pirfenidone treatment for patients with atypical liver function
MX2011009988A (es) 2009-03-23 2011-11-18 Univ Chicago Metodos para la prevencion y el tratamiento de trastornos epiteliales inducidos por radiaciones.
CN102811762B (zh) * 2009-08-12 2014-08-27 皇家飞利浦电子股份有限公司 用于药物输送装置的药物容器
US20110060040A1 (en) 2009-09-04 2011-03-10 Xenoport, Inc. Uses of acyloxyalkyl carbamate prodrugs of tranexamic acid
EP2538956A4 (en) 2010-02-22 2015-04-22 Edge Therapeutics Inc METHODS AND COMPOSITIONS FOR TREATING HEMORRHAGIC BRAIN DISORDERS
KR101820977B1 (ko) 2010-09-23 2018-01-22 인플라마겐 세린 프로테아제 억제제의 위로의 투여
US9295715B2 (en) 2010-10-02 2016-03-29 The Regents Of The University Of California Minimizing intestinal dysfunction
JP6148454B2 (ja) * 2011-11-11 2017-06-14 ロート製薬株式会社 トラネキサム酸を含む外用及び内服用組成物
ES2375784B1 (es) 2011-12-22 2013-01-24 Laboratorios Kin S.A. Gel de ácido tranexámico
CN103565743B (zh) * 2012-07-23 2016-06-22 上海市徐汇区中心医院 氨甲环酸皮肤外用纳米制剂及其制备方法和用途
WO2014028052A1 (en) 2012-08-17 2014-02-20 The University Of Chicago Materials and methods for preventing and treating anastomotic leaks
CN103054861A (zh) * 2012-12-29 2013-04-24 北京阜康仁生物制药科技有限公司 一种含氨甲环酸的复方固体制剂
US20140271923A1 (en) 2013-03-14 2014-09-18 Christopher Brian Reid Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions
KR102397379B1 (ko) 2014-03-25 2022-05-13 리딩 바이오사이언시즈, 인크. 자가소화의 치료용의 조성물
US20150297619A1 (en) 2014-04-17 2015-10-22 The Regents Of The University Of California Methods and compositions for preserving the mucosal barrier

Similar Documents

Publication Publication Date Title
JP2017515888A5 (enExample)
JP2013518107A5 (enExample)
JP2019515908A5 (enExample)
JP2018530592A5 (enExample)
HRP20180007T1 (hr) Formulacija koja sadrži gemcitabin-predlijek
RU2018114447A (ru) Введение дейтерированных усилителей cftr
JP2016510326A5 (enExample)
RU2012101881A (ru) Производные азапептидов
RU2010114033A (ru) Применение ингибитора nf-каппа в sn50 и необязательно ангиотензина iii в качестве терапевтических средств при лечении, например, инфекции hbv
JP2008001724A5 (enExample)
JP2013518056A5 (enExample)
JP2015529234A5 (enExample)
RU2013138672A (ru) Способ, композиция и набор для чистки кишечника
JP2016512210A5 (enExample)
JP2015500702A5 (enExample)
JP2016511753A5 (enExample)
FI3817751T3 (fi) Vedettömän natriumtiosulfaatin formulaatioita
JP2019535760A5 (ja) ガボキサドールを用いた注意欠陥多動性障害（ａｄｈｄ）の治療方法
JP2016529306A5 (enExample)
JP6648106B2 (ja) 自己消化の治療用組成物
JP2017200948A5 (enExample)
RU2013112807A (ru) Композиция для доставки активных агентов в желудок
HRP20210010T1 (hr) Injekcijske farmaceutske formulacije lefamulina
RU2008111148A (ru) Применение комплексных соединений железа (iii) для производства лекарственного средства для перорального лечения железодефицитных состояний у больных, страдающих хроническими воспалительными заболеваниями кишечника
CN104114165B (zh) 用于治疗憩室病的方法和组合物